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ABSTRACT 
Objective: We performed meta-analyses of randomized controlled trials to examine the effects of 
neurofeedback on attention-deficit/hyperactivity disorder (ADHD) symptoms and 
neuropsychological deficits in children/adolescents with ADHD. Method: We searched Pubmed, 
Ovid, Web of Science, ERIC and CINAHAL through August 30, 2015. Random-effects models 
were employed. Studies were evaluated with the Cochrane Risk of Bias (RoB) tool. Results: We 
included 13 trials studies (520 ADHD participants). Significant effects were found on ADHD 
symptoms rated by assessors most proximal to the treatment setting, i.e., the least blinded outcome 
measure (Standardized Mean Difference [SMD]: ADHD total symptoms=0.35, 95% CI=0.11-0.59; 
inattention=0.36, 95% CI=0.09-0.63; hyperactivity/impulsivity=0.26, 95% CI=0.08-0.43). Effects 
were not significant when probably blinded ratings were the outcome or in trials with active/sham 
controls (except for a small effect [SMD=0.21, 95% CI=0.01-0.42] for most proximal 
hyperactive/impulsivity ratings in sham/active control trials). Results were similar when only 
Frequency Band Training trials, the most common neurofeedback approach, were analysed 
separately. Effects on laboratory measures of inhibition (SMD=0.44, 95% CI=0.07-0.80 
SMD=0.30, 95% CI= -0.10-0.70), and but not attention (SMD=0.07, 95% CI= -0.19-0.33 
SMD=0.13, 95% CI= -0.09-0.36) were not significant. There were significant e. Only four studies 
directly assessed if learning occurred after neurofeedback training. The risk of bias was unclear for 
many RoB domains in most studies. Conclusions: Evidence from well-controlled trials with 
probably blinded outcomes currently fails to support neurofeedback as an effective treatment for 
ADHD. Future efforts should focus on implementing standard neurofeedback protocols, ensuring 
learning and optimizing clinically relevant transfer. 
  
3 
Introduction  
 
Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder 
characterized by age-inappropriate and impairing inattention and/or hyperactivity/impulsivity 1, 2. 
Among currently available treatment options, psychostimulant and non-stimulant medications are 
efficacious, at least in the short-term, and widely used 3. Non-pharmacological interventions - both 
dietary and psychological – have been also extensively investigated 4-7.  Among non-
pharmacological approaches, neurofeedback has been considered a promising ADHD treatment 
strategy since the early 1970s 8-10. When applied to ADHD, neurofeedback is intended to reduce 
ADHD symptoms by targeting aberrant patterns of brain activity thought to underpin the condition. 
Neurofeedback is implemented through the training of self-regulation using operant reinforcement 
procedures; learning of self-regulation is thus a key mechanism. To achieve this aim, 
electroencephalogram (EEG) indices of interest are converted into visual or acoustic signals and fed 
back automatically in real time to the patient. For instance, cortical activity may be represented by 
the height or speed of a ball, plane or cartoon character presented using animation on a computer 
screen. In this case, learning occurs when the object rises, falls, or advances more quickly in 
response to patients’ regulated changes in brain activity. Two general neurofeedback approaches 
have been used to treat ADHD: Frequency Band Training (FBT) and Slow Cortical Potential 
training (SCP). When applied to ADHD, the former is intended to target alterations of cortical 
electrical oscillations thought to be associated with ADHD, namely elevations of slow, relative to 
fast, brainwave activity - especially in the frontal lobes (e.g., theta versus beta frequency 11). The 
latter aims to regulate cortical excitation thresholds by focusing on activity generated by external 
cues (similar to event-related potentials), focusing primarily on EEG components registered in the 
late latency range, i.e., several seconds after the cue. For instance, this form of training has been 
used to target the contingent negative variation (CNV) which occurs during this time window and is 
involved in effective preparation, decision-making and time estimation, which have all been found 
to be deficient in individuals with ADHD, or at least in subgroups of them 12, 13.  
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The efficacy of non-pharmacological treatments for ADHD, including neurofeedback, has 
been subject to a number of earlier meta-analytic reviews 14-16. However, these have sometimes 
been difficult to interpret because of the inclusion of studies with weak experimental designs (e.g., 
no control arm, non-random allocation or the use of unblinded measures), as discussed in Sonuga-
Barke et al. 17. On behalf of the European ADHD Guidelines Group (EAGG), Sonuga-Barke et al. 17 
attempted to address these limitations through a meta-analysis of non-pharmacological interventions 
which included only randomised controlled trials (RCTs). It also addressed the issue of blinding by 
comparing outcomes rated by individuals judged to be most proximal to the therapeutic setting 
(often parents poorly blinded and invested in the therapeutic outcome) and those provided by 
reporters judged to be probably blinded. They found that the effects of neurofeedback on ADHD 
total symptoms based on most proximal ratings were highly significant (SMD=0.59, 95% CI=0.31-
0.87). However, when only probably blinded measures were employed, the effects became non-
significant (SMD=0.29; 95% CI= -0.02-0.61). More recently, Micolaud-Franchi and colleagues 18 
followed a similar approach, focusing their analyses on ADHD core symptoms, but with a smaller 
set of studies (n=5) limited to trials with particular control conditions. As in Sonuga-Barke et al. 17, 
they found a significant, positive effect of neurofeedback on ADHD core symptoms when 
considering most proximal raters. Probably blinded scores were attenuated and were significant 
only for symptoms of inattention.  
Applying the same meta-analyses protocol used in recent EAGG reviews of behavioural 
interventions 5 and cognitive training4, we here extend the focus of meta-analytic evidence relating 
to neurofeedback for ADHD in a number of ways. First, we included, among the outcomes, not only 
specific ADHD behavioral dimensions (i.e., inattention and impulsivity/hyperactivity) but also 
ADHD-related neuropsychological deficits such as inhibitory dysfunction. The latter may be 
important as they may take us closer to neural mediators of the behavioural effects of 
neurofeedback 9. Second, we addressed the relative efficacy of different types of neurofeedback by 
restricting sub-analyses to specific types of treatment protocols, i.e., FBT. Third, we examined the 
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impact of different aspects of trial design (e.g., use of a sham/placebo design) or pragmatic  
“dosage” characteristics of neurofeedback implementation (i.e., number of sessions). Fourth, we 
addressed the crucial question of whether neurofeedback-related learning at the neural level was 
investigated and/or demonstrated in available trials 9. Fifth, we examined whether the 
neurofeedback protocols employed in these studies could be considered “standard” in terms of the 
criteria discussed by Arns et al. 19, which include elements related to EEG bands/measures, 
electrode placement and type and feedback following learning. Finally, we applied, for the first time 
in a meta-analysis of neurofeedback for ADHD, a rigorous assessment of study bias, i.e., the 
Cochrane risk of bias tool (RoB) 20. 
 
Method 
The EAGG protocol was originally registered on the International Prospective Register of 
Systematic Reviews PROSPERO (http://www.crd.york.ac.uk/PROSPERO, protocol number: 
CRD42011001393). As in Daley et al. 5 and Cortese et al. 4, the original protocol was adapted to 
take account of the broader scope of this systematic review/meta-analysis. Most crucially, given 
that the scope of this analysis included neuropsychological measures, the mandatory requirement 
for studies to have ADHD symptoms-related outcome no longer applied (i.e., we included also 
studies presenting only neuropsychological outcomes).  
Inclusion and Exclusion Criteria 
To ensure high levels of methodological adequacy as recommended by the Cochrane group 
and to avoid the inevitable bias caused by dependence on investigators agreeing to provide data 
from unpublished studies 20, only published studies were included. Only RCTs using neurofeedback 
training were retained. Participants in the trials were required to be between 3 and 18 years of age, 
and to have a diagnosis of ADHD diagnosis (any subtype) or Hyperkinetic Disorder (HKD), or 
meet accepted cut-offs on validated ADHD symptom rating scales. Trials that selected children with 
ADHD who had rare comorbid disorders (e.g., fragile X syndrome) were excluded. Control 
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conditions allowed were “treatment as usual,” “wait list,” “active” or “placebo/sham” (i.e., 
involving other forms of alternative training regimen). As per the EAGG protocol, trials where 
neurofeedback was compared only with optimised medication or where the additional effects of 
neurofeedback when added to optimized medication were excluded. Trials where medication was 
part of background normal clinical provision in either the control or the active arm were included.  
Search Strategy 
Details about the search strategy and syntax for each database are reported in Supplement 1.  
The final search was updated on August 30, 2015. Independent searches were conducted by XX and 
XX and led to the same number of references. 
Outcome Measures 
To provide analytical robustness and in line with previous EAGG meta-analyses 4, 5, 17, 20 
using the same methodology, analyses of outcome domains were only considered reliable if at least 
five RCTs were available. The planned outcomes included: ADHD symptoms (total ADHD and 
inattention and hyperactivity/impulsivity symptoms separately), neuropsychological laboratory-
based measures, measures of academic functioning, and rating of severity of symptoms of comorbid 
conditions (e.g., oppositional defiant disorder or anxiety disorders).  
Study Selection 
Retrieved references were independently screened and blindly double-coded for eligibility 
by XX and XX. Any disagreement between these two authors was resolved by a senior author 
(XX).  
Study bias assessment 
Study quality was assessed independently by pairs of raters from the authorship group using 
the Cochrane RoB 20. RoB domains included: selection bias, performance bias, detection bias, 
attrition bias, and other bias. Any disagreement between the two raters was resolved through 
consensus. 
Data Extraction and Statistical Analysis  
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Trial information was entered into RevMan 5.3 21. Data extraction was independently 
performed and crosschecked by the first two authors. SMD was calculated as mean pre- to post-
treatment change in the intervention group minus the mean pre- to post treatment change in the 
control group, divided by the pooled pre-test standard deviation with a bias adjustment 22. SMDs for 
each trial were combined using the inverse variance method. Given the inherent heterogeneity of 
studies, random effects models were used. The I2 statistic was calculated a posteriori to estimate 
between-trial SMD heterogeneity. When multiple measurements were available for an outcome, the 
most frequently reported outcome across trials or the outcome that was judged to better tap the core 
of the construct was selected. To be consistent with the EAGG protocol and previous EAGG meta-
analyses, we considered as probably blinded those outcomes rated by an individual who was likely 
unaware of treatment allocation. Most proximal ratings were based on assessors close to the 
therapeutic setting and often unbleinded. These ratings typically constituted a trial’s own primary 
outcome measure and were therefore the assessment most available for analysis.  
Selection of most proximal and probably blinded ratings was based on independent 
judgements and consensus of three authors (XX, XX and XX). Where two or more probably 
blinded ratings were available (which was sometimes the case on sham controlled trials) what was 
deemed the best probably blinded outcome was selected for analysis, as in Cortese et al. 4. When 
there were two or more neuropsychological outcome measures, the one most frequently reported 
across the relevant trials was selected. Four sensitivity analyses were conducted. The first included 
only trials employing an active or sham control. The second was restricted to FBT trials. The third 
examined the effect of co-treatment with medication and was restricted to studies with no/low levels 
of medication (< 30% of participants on medication, as per EAGG protocol). The final sensitivity 
analysis included only studies meeting the criteria defining a standard neurofeedback methodology 
described by Arns et al. 19. Meta-regression was conducted to assess the effects of number of 
training sessions. Publication bias was assessed with funnel plots and Egger’s tests. Analyses were 
conducted using RevMan 5.3 21 and STATA 13.1 23.  
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Results 
Thirteen trials 24-36  met entry criteria. Figure 1 presents the PRISMA selection flowchart. 
Supplemental Table S1 provides a list of excluded papers with reasons for their exclusion. Retained 
studies included a total of 520 ADHD subjects. Table 1 gives information about the characteristics 
of the retained trials. Seven trials had no/low medication levels, as defined above. Results of all 
analyses are summarized in Table 2. There were less than five studies available to examine some of 
the planned outcomes such as working memory, parent ratings of executive functioning (e.g., 
Behaviour Rating Inventory of Executive Function 37), academic functioning (e.g., reading or 
arithmetic ability), or comorbid conditions (e.g., ODD, anxiety). Therefore, we did not perform 
analyses for such outcomes. 
When most proximal assessments were the outcome, there was a small-to-moderate (SMD < 
0.5) but significant effect on inattention, impulsivity/hyperactivity and total ADHD symptoms 
(Figure 2). In sensitivity analyses considering only trials with an active/sham control, the effects 
dropped to non-statistically significant levels for total ADHD and inattention symptoms. The effect 
was significant for hyperactivity/impulsivity but with a small effect size (SMD=0.25) and the 95% 
CI was wide (CI=0.03-0.47). When probably blinded outcomes were analysed, effects sizes for 
ADHD outcomes dropped further and none were significant (Figure 3). Results were also not 
significant when considering only probably blinded measures from trials with active/sham control 
(Table 2). When considering only trials with FBT, results were significant for ADHD total 
(SMD=0.37, 95% CI=0.09-0.64) and hyperactive/impulsive symptoms (SMD=0.26, 95% CI=0.06-
0.46) from most proximal raters, but not for ADHD inattentive symptoms or any ADHD symptoms 
rated by probably blinded assessors. There were insufficient trials (n=230, 32) for an analysis focused 
on SCP training (two studies also used both SCP and FBT 31, 33). When pooling only trials with 
no/low medication, results were significant only for ADHD inattentive symptoms, most proximal 
(SMD=0.59, 95% CI=0.31-0.88) and hyperactive/impulsive symptoms, most proximal (SMD=0.32, 
95% CI=0.06-0.58). 
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When the analysis was restricted to only the seven trials that met Arns et al. 19 criteria for 
use of standard protocol, the SMDs increased for most proximal outcomes although the 95% CIs 
were wide (Table 2). There were only three trials 27, 30, 31 that both employed a standard protocol and 
had probably blinded measures. In an exploratory analysis with these three trials, there was a non 
significant effect on inattention (SMD=0.31, 95% CI: -0.08-0.69) or hyperactivity/impulsivity 
symptoms (SMD=0.11, 95% CI= -0.29-0.52). T the effect on total ADHD symptoms was 
significant (SMD=0.36), although the 95% CI was large (0.04-0.69).  
 The analysis of neuropsychological outcomes required the pooling of diverse 
neuropsychological measures within general domains (Table 1). Effects were only significant for 
inhibitory control and even then there were wide confidence intervals (SMD=0.44, 95% CI=0.07-
0.80). Effects on laboratory measures of inhibition (SMD=0.30, 95% CI= -0.10-0.70), and attention 
(SMD=0.13, 95% CI= -0.09-0.36) were not significant. 
Direct evidence that neurofeedback training led to learning was gathered in only four trials 
27, 29, 33, 36 and was positive for just one 27. In one study 29 there was a partial learning effect. In 
Heinrich et al. 32 there was indirect evidence of learning: the increase of the contingent negative 
variation (a slow cortical potential) suggests that children learned what was trained. 
Studies varied considerably in terms of risk of bias (Supplemental Figure S1). For 
approximately half of the RoB domains across studies, the level of risk was unclear. For those 
categories that could be determined, eight trials were rated as having a high risk of bias in at least 
one domain. In general, the major concern (i.e., high risk of bias) related to blinding of participants, 
personnel, and assessors. Among “other bias”, funding was not clearly stated in a sizable portion of 
studies (for further details, see Supplemental figure S1). 
Funnel plots and Egger test results (Supplement 2) suggested little evidence of publication 
bias although the number of trials was insufficient to establish a reliable estimate. Finally, meta-
regression analyses did not support a relationship between number of training sessions and most 
proximal or probably blinded outcomes (Supplement 3).  
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Discussion  
The rationale for the use of neurofeedback for ADHD rests on the idea that promoting 
normalization or self-regulation of brain activity will translate into improved cognitive and 
behavioural control that is deficient in individuals ADHD. A previous meta-analysis 17, based on a 
limited number of trials (n=8), was inconclusive with regard to the efficacy of neurofeedback for 
ADHD symptoms. Although there were moderate but highly significant effects (SMD=0.59; 95% 
CI=0.31-0.87) for ADHD outcomes rated by most proximal assessors, these were not significant 
when only probably blinded outcomes were considered (SMD=0.29; 95% CI: -0.02 -0.61). The 
current meta-analysis, including an additional five RCTs, provides what is likely to be a more 
reliable estimate of the effects of neurofeedback for ADHD. Importantly, the additional statistical 
power also allowed us to explore the impact of neurofeedback type, the effect of type of control, the 
impact of number of NF sessions, and the value of using standard neurofeedback procedures. 
Although it does not provide a definitive statement as to the ultimate value of neurofeedback, the 
current analysis has clarified a number of issues. 
In general, the effect size estimates in the current analysis are substantially smaller 
compared to the previous one by Sonuga-Barke et al. 17. This is due to the smaller effect sizes 
reported in the most recent trials, not included in Sonuga-Barke et al. 17. For instance, SMDs 
dropped for most proximal and probably blinded total ADHD outcomes by 41% and 49%, 
respectively – although the analysis based on most proximal ratings of ADHD core symptoms 
remained significant. Crucially, as in the previous meta-analysis 17, when the risk of biased effect 
size estimates was reduced either by selecting probably blinded outcomes or limiting analysis to 
trials with a high-quality control arm (sham or active), effects were no longer significant. 
Importantly, and in contrast to previous meta-analyses 15, 18, there was no evidence for a particular 
benefit with regard to inattention symptoms – which have previously been hypothesized to be more 
amenable to neurofeedback. This was also reflected in our failure to find effects on laboratory 
measures of attention such as the continuous performance test., and somewhat surprisingly perhaps, 
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we did find a significant effect of neurofeedback on laboratory measures of inhibitory control. 
However, this deserves further study since the confidence intervals around the SMD estimate were 
large and the measures included in these analyses as reflecting inhibitory control were quite diverse.  
 Previously, Sonuga-Barke et al. 17 have argued that the substantial drop in SMDs between 
most proximal and probably blinded analyses is likely to be result of biases in perception in favour 
of the active treatment when one relies on observations by raters aware of treatment allocation.  
However, there are some other explanations. For instance, it is possible that probably blinded 
ratings are, for some reason, less sensitive to change than most proximal measures – perhaps either 
because of the instruments used or the person rating. Teachers, for instance, may be less sensitive to 
change than parents. However, essentially the same questionnaires were completed by both these 
types of raters. It is also possible that proximal ratings accurately reflected real improvements in the 
setting where the treatment was delivered but these effects failed to generalise to more distal 
settings where blinded measures were recorded. This explanation seems unlikely as probably 
blinded measures were collected in the treatment setting also for some trials and these followed the 
same pattern. The type of neurofeedback protocol implemented in the trials did not seem to be an 
important factor in determining the results. When we restricted the analysis to trials using some 
form of FBT such as that focusing on alteration of the ratio between slow theta and faster beta 
oscillations, there was no increase in the effects of treatment. There was an insufficient number of 
trials (n=2) 30, 32 using SCP training exclusively to state any firm assertion about this approach. The 
results raise the question of whether current training protocols have the appropriate treatment target. 
For instance, the developmental stability of EEG frequency band alterations in ADHD from 
childhood into adulthood have been questioned 11, 38, 39, while the most commonly observed ADHD 
effects with regard to evoked brain responses relate to early rather than later components not 
targeted in current neurofeedback protocols. Therefore, the rationale for theta-beta and slow cortical 
potentials feedback have been very critically discussed (e.g., 9, 40).  
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The value of a treatment meta-analysis is of course constrained by the methodology of the 
trials they include. It is, therefore, possible that the results of our meta-analysis reflect the 
methodological weaknesses of the included studies rather than the weakness of neurofeedback as 
such. Indeed, the current set of 13 trials, taken as whole, had a number of methodological short-
comings. First, only four studies tested 27, 29, 33, 36, and then just one 27 reported directly and 
positively, whether neurofeedback training had actually led to learning as indexed by 
changes/improvement at the electrophysiological level. In the one positive trial 27, the mediating 
role of changes in the electrophysiological signature leading to changes at symptom level was not 
investigated. This is a crucial point because if neurofeedback cannot bring about the expected 
changes at the neural level, then treatment effects are more likely to be artifacts of some other non-
specific aspect of the training. Such a situation may be similar to cognitive training targeting but not 
improving working memory, or to a drug with an established neurotransmitter profile not reaching 
the corresponding neural target system in the patient's brain. On the other hand, tests for learning of 
neural self-regulation, and addressing relations between learning and  clinical improvement, would 
also need to consider more complex models and alternative mechanisms, for example allowing for 
initial, delayed, and nonlinear types of learning and translation 41, before concluding that effects are 
non-specific. Further research should address whether possible neuronal modifications underpin 
putative behavioral changes in ADHD symptoms following neurofeedback.  
A number of groups have defined what constitutes a standard neurofeedback protocol in 
terms of the number of training sessions, the reinforcement parameters operating, the EEG montage 
etc. (see Vernon et al. 2004 42 for a justification). Interestingly only 54% of the studies in the 
current analysis met such a threshold. When we restricted the analysis to that subset of trials our 
results were somewhat mixed – the effect size for total ADHD and inattention increased by about 
20%; however, for all most proximal outcomes, 95% CIs were wide and close to non significance. 
Unfortunately, there were only three studies with a standard protocol including probably blinded 
ratings 27, 30, 31, so that firm conclusions on the value of standardised protocols as defined by Arns et 
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al. 19 cannot be drawn. In addition, the level of methodological rigour specifically related to RCT 
conduct, as explored by the RoB, was in general unclear. The level of blinding was unclear or 
insufficient in many studies. Additionally, one particularly striking omission in the majority of trials 
was the report of possible potential conflicts of interest. This would seem to be a major oversight in 
the current literature, given the growing presence of neurofeedback training companies in the 
commercial treatment marketplace. Given these limitations, it seems that without evidence for the 
learning of self-regulation and given the wide spread use of non- standard neurofeedback protocols 
it is hard to draw definitive conclusions about the ultimate value of neurofeedback approaches.  
EAGG have also recently completed meta-analyses for behavioural interventions and 
cognitive training using the same core protocol as used here 4, 5. There are striking similarities but 
also some differences between the results of the present meta-analysis and those from these recent 
EAGG meta-analyses. In terms of effects on ADHD symptoms, neurofeedback, cognitive training 
and behavioural interventions show almost identically sized positive and statically significant 
effects on total ADHD symptoms scores rated by most proximal assessors (SMD: behavioural 
interventions=0.35; cognitive training=0.37; neurofeedback=0.35). Furthermore, in all three cases, 
the effects drop substantially to non-significant levels when probably blinded outcomes are used. 
This is more evident for behavioural interventions where the effects drop to zero but is also 
substantial for neurofeedback and cognitive training (SMD=0.15 and 0.20 respectively). However, 
one quite striking difference between the three meta-analyses is that both behavioural interventions 
and cognitive training had predictable positive effects on outcomes other than ADHD. For instance, 
for working memory training, there were highly significant effects on neuropsychological measures 
of working memory, while behavioural interventions improved parenting rated by independent 
observers and had positive effects on probably blinded measures of conduct problems. The By 
contrast, we did not find evidence for effects of neurofeedback on neuropsychological outcomes.  
Caution is required when interpreting these findings given a number of limitations, in 
addition to the issues raised with regard to the nature of the trials above. First, effects size estimates 
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may be inflated because of the failure to report intention to treatment analyses in most trials. 
Second, there were insufficient trials measuring important outcomes such as working memory task 
performance, academic skills, general functional impairment, IQ and other mental health problems 
such as conduct problems. Third, few trials included long-term outcomes (see Table 1) to allow an 
evaluation of the extent to which effects on clinical symptoms grew over time or effects on 
neuropsychological processes persisted. Fourth, no trial recruited subjects based on the presence of 
ADHD-related deficits in EEG signature (i.e., altered theta-beta ratio). This may limit the chance 
for neurofeedback related improvements in symptoms. Fifth, it was necessary to pool data from 
diverse measures from different tasks to have sufficient trials to analyse neuropsychological 
functions. Although in principle the pooled measures tapped the same neuropsychological domain, 
this inevitably was a somewhat arbitrary process which likely increased SMD heterogeneity. 
AdditionallyLastly, ADHD is a pathophysiologically heterogeneous disorder and distinct EEG 
subtypes have been described (e.g., cortical hyperarousal vs. hypoarousal subtypes). Patients might 
require more specific and tailored training targeting different deficits associated with ADHD. 
Combining different neuroimaging approaches with NF training might be a useful approach in the 
future. Finally, the range of number of sessions across studies may have been too restricted to allow  
the detection of possible effect of session number. 
 In summary, the current meta-analysis shows that evidence from well controlled and with 
probably blinded outcomes does not support neurofeedback as an effective treatment for ADHD– 
either in terms of ADHD symptoms or other cognitive correlates, with the possible exception of 
inhibitory control. Future research should focus on (i) identifying the most appropriate 
electrophysiological treatment target; (ii) increasing the use of standard EEG and learning protocols 
(iii) developing new methods to optimise the chances that neurofeedback leads to learning at the 
brain level and (iv) identifying predictors of treatment response for individual patients or at least in 
distinctive subgroups of children.  
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Table 1. Characteristics of studies included in the meta-analysis. Studies are listed in alphabetical chronological order of publication.  
TRIAL A DESIGN TRAINING SAMPLE OUTCOMES 
 Control 
Type 
NF 
Standard 
Protocol  B 
N 
sessions 
Follow-
up 
(months) 
N C 
t 
c 
meds (%) 
t 
c 
age 
(mo.) 
ADHD symptoms     Neuropsychological outcomes 
 
    
    
M- 
PROX 
P- 
BLIND 
Inhibitory  
control 
Attention 
Arnold 
(2012) 26 
 
Sham 
placebo D 
 
FTB E no 40  
 
2 
 
25 
11 
0  
0 
72-144 Parent Teacher  
 
BRC 
Bakhshayesh 
(2011) 27 
 EMG 
biofeedback 
FTB  yes  30  
 
6 F 
 
18 
17 
22 
18 
 
72-168  
Parent Teacher 
CPT 
(commission) 
CPT (omission) 
Beauregard 
(2006) 28 
 No 
treatment 
FTB G yes  
 
40  
 
 
N/S 
 
15 
5 
0 
0 
 
96-144  
Parent N/A 
Counting 
Stroop 
(interference) 
CPT (integrated 
visual and 
auditory) 
Bink  
(2014) 29  
 TAU FTB H no 
 
37  
 
 
12 
 
45 
26 
 44.4 
 61.5 
193.2 
±39.6 
(T) 
194.4 ± 
40.8(C) 
Parent N/A 
Colour Stroop 
(Interference) 
 
D2 attention 
(total correct) 
Christiansen  
(2014) 30 
 
 Self-manag. SCP  yes  30  
 
     12 
 
 
58 
(tot.) 
23 I, L 
101.04 
± 16.08  
Parent Teacher  
 
 
 
Gevensleben  
(2009) 31  
 
AT 
SCP 
plus 
FTB M 
yes  
 
36 
 
 
6  
 
59 
35 
8.5 
2.9 
118 
±15 (T) 
112 ± 
14 (C) 
Parent Teacher 
ANT, 
Orienting  
(data from 47, 
that refers to 
the same 
sample of 31) 
ANT,  
Conflict 
(data from 47, 
that refers to the 
same sample of 
31)  
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Heinrich  
(2004) 32  
  
WL 
 
SCP N yes 
25 
 
 
N/S 13 
9 
46.1 
44.4 
 
90-165 
 
Parent NA 
CPT 
(commission) 
 
CPT (omission) 
Holtmann 
(2009) 25 
 AT O FTB N 
 
yes 
 
 
20 
 
N/S 
20 
14 
79.4 P 
123.6± 
14.4 
mean  
Parent N/A 
Stop Signal 
Task  
 
 
 
Linden 
(1996) 24 
 WL FTB  yes 
 
40 
 
N/S 
8 
6 
0 
0 
 110 
(mean) 
Parent N/A  
 
Maurizio 
(2014) 33 
EMG 
biofeedback 
SCP 
plus 
FTB Q 
no 
 
36 
 
 
N/S 
13 
12 
7.6 I 
8.3 I 
102 -
154.8  
 
Parent Teacher  
D2 attention 
(total score) 
Steiner 
(2011) 34 R 
 AT O, WL  S FTB H no 
 
23 
 
 
N/S 
9 
11 
60 
148.8±
10.8 
Parent Teacher  
 
Steiner 
(2014) 35 
 
CT, WL S 
 
FTB H no 
 
40 
 
 
6r T 
 
34 
34 
44.1 
41.1 
100.8±
13.2 
(T) 
106.8±
12.0 
(C) 
Parent BOSS  
 
VanDongen 
(2013) 45 
Vollebregt  
(2014) 36, s U 
  
Placebo NF 
 
FTB t V 
 
no 
  
 
30 
 
 
6 u Z 
 
22 
19 
54.5 
73.7 
126.0±
26.4 
(T) 
128.4±
27.6 (C 
Investi
gator 
Teacher  
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ANT: Attention Network Test; AT: attention training; CPT: continuous performance test; CT: cognitive training; BOSS: Behavioral Observation of 
Students in Schools; BRC: brain resource center computer based normed neuropsychological test, C: Control Group; CPT: Continuous Performance 
Test; FTB; frequency theta/beta; N/A; not applicable; N/S: Not specified; SCP: Slow Cortical Potential; SMR: sensory motor rhythm; SST: Stop 
Signal Test ; Training Group; TAU: Treatment As Usual 
 
A In alphabetic order, followed by study reference number; B Standard methodology described by Arns et al. 19; C N is the number of individuals in 
the Treatment (T) and Control (C) conditions; D Equal intensity and duration; E  Cz vs ears; F Results of the follow-up were not published in this 
paper; G SMR+beta; ; H SMR; I Children were off medication 48 h prior to all the assessments; L Number in each group not specified; M SMR+beta  
Cz-ears; N Calculated from Cz vs mastoids; O standard computer format; P A total of n=27 were medicated (not indicated how many in each group); 
Q B=beta, LORETA Tomography; R  We used Parent#1 since parent #2 measures were available for a smaller sample (n=9 for parent #1 and n=5 for 
parent #2 in NF and n=11 for parent #1 in n= 9 for parent #2 in the waiting list group); for a discussion of the outcomes selected from this study, 
please see Arns and Strehel, 2013 48 and Sonuga-Barke et al., 2013 49;  S: The WL arm was used as comparator in the analyses; r  T The results of the 
follow-up phase were published in Steiner et al. 43; s U These two papers refers to the same study and present analyses on different outcomes; t V 
Individualized, mainly T/B, B=SMR; u Z data only reported at endpoint (15 weeks) 
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Table 2. Summary of results. Pooled standardized mean differences (SMD) for each outcomes. 
Significant effects are bolded. Positive SMDs indicate that neurofeedback is more efficacious 
than control condition. 
Outcome 
Trials 
included 
Measure 
Number 
of trials 
Effect of Intervention Heterogeneity 
    SMD 95% CI p I2 p 
ADHD symptoms 
Total 
All 
MPROX 13 0.35 0.11, 0.59 0.004 41 0.06 
PBLIND 8 0.15 -0.08, 0.38 0.20 0 0.74 
Active/sham  
MPROX 7 0.22 -0.08, 0.52 0.14 35 0.16 
PBLIND 6 0.20 -0.05, 0.45 0.12 0 0.66 
FBT 
MPROX 9 0.37 0.09, 0.64 0.01 36 0.13 
PBLIND 5 0.03 -0.29, 0.35 0.84 0 0.76 
Low 
medication 
MPROX 7 0.39 -0.01, 0.79 0.05 48 0.08 
PBLIND 5 0.26 -0.01, 0.54 0.06 0 0.76 
Standard 
Protocol 
MPROX 7 0.45  0.02, 0.88 0.04 53 0.05 
inattention 
All 
MPROX 11 0.36 0.09, 0.63 0.009 43 0.07 
PBLIND 7 0.06 -0.24, 0.36 0.70 41 0.12 
Active/sham 
MPROX 6 0.26 -0.10, 0.63 0.16 49 0.08 
PBLIND 5 0.21 -0.09, 0.50 0.17 16 0.31 
FBT 
MPROX 9 0.33 0.00, 0.67 0.05 51 0.04 
PBLIND 5 -0.04 -0.37, 0.28 0.79 19 0.29 
Low 
medication 
MPROX 6 0.59 0.31, 0.88 0.0001 0 0.63 
PBLIND 5 0.19 -0.12, 0.50 0.23 21 0.28 
Standard 
Protocol 
MPROX 5 0.55 0.01, 1.09 0.05 58 0.05 
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hyper/imp 
All 
MPROX 10 0.26 0.08, 0.43 0.004 0 0.80 
PBLIND 7 0.17 -0.05, 0.39 0.13 0 0.59 
Active/sham 
MPROX 6 0.25  0.03, 0.47 0.03 0 0.92 
PBLIND 5 0.15 -0.11, 0.41 0.26 0 0.80 
FBT 
MPROX 8 0.26 0.06, 0.46 0.01 0 0.62 
PBLIND 5 0.15 -0.15, 0.44 0.33 6 0.37 
Low 
medication 
MPROX 5 0.32 0.06, 0.58 0.02 0 0.44 
PBLIND 5 0.12 -0.15, 0.38 0.39 0 0.52 
Standard 
Protocol 
MPROX 5 0.28 0.02, 0.53 0.04 14 0.32 
Neuropsychological Test Performance 
attention  
All objective 8 0.13 -0.09, 0.36 0.26 0 0.72 
FBT objective 5 0.11 -0.16, 0.38 0.43 0 0.76 
inhibition  All objective 6 0.30 -0.10, 0.70 0.15     56 0.05 
 
Only outcomes are reported where five or more trials met inclusion criteria. There were insufficient 
trials for: standard NF, PBLIND tot (n=3), PBLIND In (n=3); Standard protocol, MPROX, hyp/imp 
and PBLIND (tot, In, hyper/imp) (n=3); FBT, inhibition (n=4 trials); Inattention, PBLIND, low 
medication (n=4); Hyp/imp PBLIND, low medication (n=4). “All” = all trials meeting inclusion 
criteria with available measures; “active/sham” = only trials with an active or sham control arm; 
FBT = trials using a version of frequency band training including theta-beta ratio training. MPROX: 
most proximal rater; PBLIND: probably blinded rater; SMT: Self-management Therapy; TAU: 
treatment as usual  
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FIGURES CAPTIONS 
Figure 1. PRISMA flow diagram of selection of studies (last search updated on August 30th, 
2015). 
Footnote 
A  Reasons for exclusion of each paper are reported in Table S1 ; B Three papers in the search (Bink 
et al. 29, Steiner et al.35  and Vollebregt et al. 36) refer to the same sample of other 3 (Bink et al. 44, 
Steiner et al. 43,  van Dongen Boomsma et al. 45, respectively); in the current meta-analysis, which is 
an update of Sonuga-Barke et al.17, we did not include the paper by Lansbergen et al. 46 (included in 
Sonuga-Barke et al. 17) since it is a pilot study included in the larger study by Vollebregt et al. 36 
(same dataset as in van Dongen Boomsma et al. 45)  
 
Figure 2. Forest plots for meta-analysis of effects on ADHD core symptoms assessed by most 
proximal (MPROX) raters. 
 
Figure 3. Forest plots for meta-analysis of effects on ADHD core symptoms assessed by 
probably blinded (PBLIND) raters. 
 
 
 
